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Abstract
Venous thromboembolism (VTE) presenting as deep vein thrombosis and 
pulmonary embolism clinically is a potentially fatal cardiovascular diseases with 
short-term and long-term sequelae. Furthermore, there is high recurrent rate in 
VTE patients during follow-up. Anticoagulation with traditional anticoagulants 
or new generation of oral anticoagulants is the gold standard treatment in patients 
with VTE. On the other hand, there is remarkable progression in device-based or 
surgical thrombectomy in managements of VTE in recent years. Current evidence 
also demonstrates the efficacy and safety of these invasive procedures in selective 
VTE patients. The present article will illustrate recent advances of device-based or 
surgical thrombectomy in VTE treatment.
Keywords: deep vein thrombosis, pulmonary embolism, catheter-directed 
thrombolysis, (mechanical thrombectomy), rheolytic embolectomy, aspiration 
thrombectomy, rotational thrombectomy
1. Introduction
Venous thromboembolism (VTE) is a set of diseases in which blood clot forms 
and occludes venous circulation and regard as the third frequent acute cardio-
vascular disease [1]. Clinically, VTE presents as deep vein thrombosis (DVT) and 
pulmonary embolism (PE) which account for two-third and one-third of VTE, 
respectively [2]. The estimated annual rate of incidence of VTE is 80 to 260 per 
100000 population [3]. In general, the incidence of VTE increases with age. One 
epidemiologic study in United States showed that the incidence of VTE was 143 
per 100000 in papulation at age 45–49 years and 1134 per 100000 in those at 
age > 80 years [4]. There is difference of incidence between ethnicities and black 
and white have higher incidence than other races [2]. Although patients with VTE 
might be asymptomatic, VTE is a potentially fatal disease. One study reported that 
the estimated annual VTE-related death was around 300000 in U.S [5] and nearly 
30% of VTE patients died within 30 days after diagnosis. Compared to DVT, PE 
accounts for majority of early-stage mortality of VTE [6, 7]. In addition to VTE-
related mortality and cardiovascular sequelae, such as post-thrombotic syndrome, 
chronic venous insufficiency and chronic thromboembolic pulmonary hyperten-
sion, etc., patients with VTE have high risk of other atherosclerotic diseases and 
acute cardiovascular events, such as acute myocardial infarction and ischemic 
stroke, in the short-term and long-term follow-up [8–10]. With a brief review 
of pathogenesis and risk factors of VTE, the following of this chapter focuses on 
percutaneous interventions for VTE.
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2. Pathogenesis and risk factors of venous thromboembolism
Virchow’s triad composed of stasis, vascular damage and hypercoagulable status 
describes the essential components contributing to the thrombus formation [11]. 
In most cases of VTE, stasis plays a major role triggering the formation of venous 
thrombosis [12]. However, the exact pathogenesis of VTE seems to be more complex 
and is not fully understood [2, 13]. Only one existing contributing factor is hard 
to result in the development of clot formation [14]. Nonetheless, the interaction 
between multiple concurrent contributing factors increases the risk of formation of 
venous thrombosis which progresses to significant VTE clinically thereafter.
In clinical aspect, many diseases and circumstances regarded as risk factors are 
identified to predispose to the development of VTE. In general, these risk factors 
are classified into genetic and acquired risk [15–18]. Genetic risk factors including 
protein C and S deficiency, antithrombin deficiency, the factor V Leiden gene muta-
tion, antiphospholipid syndrome, etc. Acquired risk factors are further divided into 
concurrent diseases (elderly, chronic diseases, active cancer, obesity) and transient 
states (surgery, trauma, hospitalization, immobility, central venous catheter or 
device indwelling, oral contraceptives, etc.) [2]. Of note, hospitalization is an 
important period that multiple risk factors encounter concurrently and increase 
the risk of VTE greatly [2, 19]. Although predisposing factors are identified in most 
cases of VTE, there are still almost 20% of case having no obvious etiology. The 
result suggests the significance of unknown genetic or acquired risk factors to the 
development of VTE [2, 3].
3. Thrombectomy in management of VTE
To date, anticoagulation is still the principal treatment in VTE. In addition to 
traditional anticoagulation, including heparin, low molecular weight heparin and 
vitamin K antagonists, as well as direct thrombin inhibitors, non-vitamin K oral 
anticoagulants (NOACs), known as direct oral-anticoagulant (DOACs) change the 
strategy in medical treatment of VTE. The update of principles and strategies of 
medical treatment of VTM will be illustrated in another chapter. On the other hand, 
endovascular or surgical thrombectomy and embolectomy have role in treatment 
of VTE. Historically, Läwen conducted the first thrombectomy for venous throm-
bosis of upper extremity in 1938 [20]. After evolution in nearly 90 years, there 
are great advances in techniques and modalities in performing thrombectomy and 
embolectomy. However, thrombectomy or embolectomy is still indicated in limited 
population in modern treatment of VTE, especially in patients with massive or 
submassive thrombus burden accompanied by unstable hemodynamic status or 
critical complications [21–23]. Theoretically, endovascular or surgical thrombec-
tomy removes majority of thrombus load more completely and recanalization of 
occluded vessels earlier [24, 25]. Moreover, some previous studies even reported 
that thrombectomy may have potential benefits comparing to anticoagulation alone 
in long-term complications and quality of life in certain VTE patients [22, 26]. The 
aim of this chapter will focus on the advances of modalities of endovascular and 
surgical thrombectomy.
4. Catheter-based therapy
Percutaneous management, also known as catheter-based therapy (CBT), for 
VTE can be divided into two mechanisms: thrombolysis-based and mechanical 
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thrombectomy. There are also devices combining these two mechanisms. For 
certain conditions, percutaneous approaches also include balloon angioplasty and 
stenting. We describe different types of CBT in the following sections.
4.1 Catheter-directed thrombolysis
Compared to systemic thrombolysis, catheter-based thrombolysis is, by 
concept, more likely a local therapy. The advantage of this approach is a reduced-
dose thrombolysis. Therefore, there is less risk of bleeding [27, 28]. Although 
with lower dosage needed, absolute contraindications for catheter-directed 
thrombolysis are the same as for systemic thrombolysis, including history of any 
intracranial hemorrhage, ischemic stroke within three months, structural intra-
cranial lesion, active bleeding, recent head, eye or spinal surgery, and recent head 
trauma [29, 30].
This approach is done by placing an infusion catheter with multiple side holes 
and a tip occluding wire or a dedicated catheter specifically for a certain device, 
preferentially into the thrombus. It may sometimes require two catheters to be 
placed in each of the main pulmonary arteries. If there is no specialized catheter, a 
standard pig-tail or pulmonary artery catheter may also serve to deliver thrombo-
lytic agent locally. When performing intervention for pulmonary embolism (PE), 
power injection may be necessary to take clear angiography to localizes the emboli. 
For each main pulmonary artery, perform contrast injection at 15–20 m/s for a total 
volume of 30 ml [28]. For intervention of deep venous thrombosis (DVT), careful 
hand injection with low-volume contrast is preferred to avoid disruption of thrombi 
with progression to PE [30].
Thrombolytic agent is administered via the carefully placed catheter. There 
is no standard for the agent and dosage used. It varies according to accompanied 
device, patients’ bleeding tendency, and physicians’ preferences. A commonly used 
regimen is tissue plasminogen activator (tPA) 0.5–1.0 mg/hr for 6–24 hours, with 
total dosage usually between 12 and 24 mg. Fibrinogen should be monitored during 
infusion of fibrinolytic agent. Dose reduction or discontinuation should be consid-
ered if level of fibrinogen falls below 150 mg/dL. During t-PA infusion, a low-dose 
heparin infusion is usually kept, with a partial thromboplastin time (PTT) just 
around the lower limit of therapeutic range, usually PTT 40–50 seconds [28, 30].
Catheter-directed thrombolysis applies for both DVT and PE. A key factor to 
success of lytic-based approach is that whether the thrombolytic agent is delivered 
into the thrombus with good penetration. A resolution to this problem is combining 
other method to enhance efficacy of drug delivery, such as the EkoSonic system.
EkoSonic™ Endovascular System (EKOS) is a device for ultrasound-assisted 
catheter-directed thrombolysis. It includes a control unit and a uniquely designed 
catheter to achieve better penetration of thrombolytics by so-called acoustic 
pulse thrombolysis. The catheter is composed of an ultrasonic core in central 
lumen, central coolant lumen, and drug delivery lumen. The ultrasonic core 
generates an acoustic field to enhance drug delivery into the clot and to unwind 
the fibrin for better exposure to thrombolytic agents. This system is indicated for 
both DVT and PE [31].
There were also devices designed for a true localized therapy. Trellis™ Peripheral 
Infusion System is a specialized device for isolated thrombolysis. It consists of two 
occlusive balloons to isolate the treatment area, an infusion zone to deliver throm-
bolytic agents, an oscillation drive unit to better disperse the drug to thrombi, and 
an aspiration window to remove the dissolved clot. Although with a unique design 
to ensure localized thrombolysis and thrombi removal, the devices were recalled 
due to incorrectly labelling of proximal and distal balloons [32].
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Of note, catheter-directed thrombolysis alone may not be sufficient to clear all 
blood clots, although it is true that the goal of catheter-directed thrombolysis for PE 
is not to remove emboli completely, but to reduce the risk from high to intermediate 
[29]. Further intervention to remove emboli and thrombi may be needed and there 
are devices combining local thrombolysis and sequential blood clot removal, which 
would be described later.
4.2 Mechanical thrombectomy
Mechanical thrombectomy is achieved by physical disruption of thrombus via 
different methods, with various devices designed for this purpose. These devices 
have different benefits, adverse effects, and special concerns while manipulation. 
Overall, they are less invasive compared with traditional surgical thrombectomy. 
Some devices achieve thrombus removal in a single session, sparing the use of 
thrombolytic agents. The following section describes devices with approval. Devices 
still under development are not covered.
4.2.1 Thrombus fragmentation
Mechanical thrombectomy without a device has long been described in both 
treatment for DVT and PE. It is usually done by a pigtail with manual rotation or 
by balloon angioplasty [28]. An important issue of fragmentation is that it might 
create distal emboli, causing worse distal obstruction; and fragmentation alone may 
not be enough to resolve obstruction. It may be followed by systemic thrombolysis, 
catheter-directed thrombolysis, or thrombi removal by manual aspiration. Due 
to lack of clinical evidence, there is no recommendation for how to combine other 
strategy after manual thrombus fragmentation.
4.2.2 Aspiration thrombectomy
Besides manual thrombus aspiration with a regular guide catheter or special-
ized catheters with greater power of suction, there are devices designed to remove 
thrombus by suction via negative pressure. The advantages are the ability to remove 
large thrombi or even chronic thrombi, avoidance of thrombolytic agents, and 
possible less risk of bleeding.
The AngioVac® system works in an extracorporeal circuit and needs two large 
venous access sites for AngioVac inflow cannula (22Fr) and reinfusion outflow 
cannula (16–20 Fr). The third generation uses funnel-shaped and different-angled 
tip (20 degree or 180 degree) to facilitate navigation. Besides the need of two large-
bore accesses, another disadvantage of this device is that perfusionist is required. 
It is indicated for removal of fresh, soft thrombi or emboli in right atrium, right 
ventricle, superior vena cava, inferior vena cava, and iliofemoral veins during 
extracorporeal bypass. It is not indicated in pulmonary vasculature although there 
are case series [33].
The FlowTriever® system includes an Triever Aspiration Catheter, a 
FlowTriever catheter, and a retraction aspiration device. Thrombus removal is 
done by manual aspiration with a syringe via the large-lumen aspiration catheter. 
There are nitinol mesh disks on the tip of FlowTriever catheter to disrupt and drag 
residual clots into the aspiration catheter for extraction. This system is indicated for 
PE [34]. A similar system dedicated for DVT is the ClotTriever® system. It includes 
a ClotTriever sheath and a ClotTriever catheter. The procedure steps are somewhat 
different. The ClotTriever catheter is position beyond the thrombus. A mesh col-
lection bag on the tip of ClotTriever catheter retracts thrombi into the ClotTriever 
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sheath with a self-expanding funnel tip, providing embolic protection. Manual 
aspiration is applied if there are residual thrombi in the sheath. Since treatment is 
completed in a single session and there is no need for thrombolysis, care in inten-
sive care unit (ICU) after procedure may not be necessary. However, a large-bore 
vascular access (20 Fr) is needed [35].
Penumbra’s Indigo® Aspiration System operates in a more “automatic” way, 
with less need of manual control. The main components of the system are a cath-
eter, a Penumbra ENGINE to generate vacuum for aspiration, and a tubing system. 
When the catheter is in position, the system performs automatic aspiration. With 
different catheters, there are corresponding Separator wires to remove clot in the 
lumen of aspiration catheters. Compared to AngioVac® and FlowTriever®, the 
Indigo® system does not require large-bore vascular access but may therefore 
unable to remove larger thrombi. It is indicated for removal of fresh, soft thrombi or 
emboli in both peripheral arterial and venous system and for treatment of PE [36].
Syringed-based thrombectomy offers limited force and aspirated volume, 
and operators could not further manipulate. Pump systems with specific devices 
provide increased force and volume but usually with increased complexity of 
the procedure and increased cost. Control Mechanical Thrombectomy™ system 
(Aspire) works in a different way. The system includes a thrombectomy catheter 
and a control mechanical aspirator which is like a handle. Through the handle, the 
operator can adjust strength of the aspirated force, and switch between continuous 
and pulsed force. It is indicated for removal of fresh, soft thrombi in peripheral 
vasculature, but not PE [37].
4.2.3 Rotational thrombectomy
The concept of rotational thrombectomy is thrombus disruption by a catheter 
with rotating head. Most devices also have the ability to remove thrombus via active 
suction.
Aspirex® mechanical thrombectomy device consists of a catheter with a 
handle and a drive system. At the tip of the catheter, there is aspiration port to 
suck in thrombi; and inside the catheter, there is rotational coil to break down 
thrombi. The fragmented thrombi are then aspirated out. The device is indicated 
for both arterial and venous thrombi. With limited case studies, it is not approved 
for treatment of PE [38].
CLEANER™ Rotational Thrombectomy System is a one-piece device. Rotating 
action of its sinusoidal wire breaks down thrombi. The sinusoidal shape provides 
atraumatic action on thrombi adhered to vessel wall. The device also enables 
infusion of thrombolytic agents via a distal side hole. It is indicated for removal of 
thrombus in peripheral vasculature, but not for PE [39].
4.2.4 Rheolytic thrombectomy
Rheolytic thrombectomy is based on Bernoulli effect. A high-velocity saline jet 
creates a low-pressure, drawing thrombi into the catheter. To eliminate thrombi 
better, it may be accompanied with thrombolysis or other mechanical method such 
as aspiration.
Among this category, the mostly studied device is AngioJet™ Rheolytic 
Thrombectomy System, consisting of a console and a thrombectomy catheter. 
The system works in both pharmacological and mechanical ways. Operators can 
deliver thrombolytic agents directly into the clot to facilitate removal of thrombus. 
The console generates pressurized saline to draw thrombi into the catheter via 
an inflow window near the tip of the catheter, and then evacuates the thrombi. 
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Notable adverse events include pain, cardiac arrythmia (mainly bradyarrhythmia), 
hypotension, transient hemolysis, bleeding, and acute kidney injury. Hydration 
before, during, and after the procedure may be considered. AngioJet™ system is 
indicated in removal of thrombi in peripheral vasculature. When used in PE, there 
were severe adverse events, including death; so, there is a “black box” warning for 
AngioJet™ in treating PE [40].
4.3 Combined thrombolytic and mechanical approaches
The concept of combination works in at least two modes. One is to combine 
multiple mechanisms at the same time, usually by devices, like EKOS or AngioJet™. 
The other way is to use different methods sequentially. For instance, physicians may 
perform balloon angioplasty first to disrupt the thrombi; and then leave an infusion 
catheter for thrombolysis. This concept also works in a reverse way. Physicians may 
place an infusion catheter for thrombolysis first, usually for 24 hours; and then 
break the loosen thrombi with balloon angioplasty. Theoretically, combing throm-
bolysis and mechanical thrombectomy improves efficacy of thrombus removal, but 
there is no standard for how to combine multiple strategies due to limited studies. 
This so-called pharmacomechanical approach is therefore, largely based on clini-
cians’ experience.
4.4 Angioplasty and stenting
Besides thrombolysis and mechanical thrombectomy, some adjuvant proce-
dures may be needed, mainly for DVT. Balloon angioplasty plays a role in chronic 
thromboembolic pulmonary hypertension, but not for acute PE. For DVT, place-
ment of inferior vena cava filter before procedure may be considered to prevent PE, 
especially for patients with poor cardiopulmonary function and deemed unable to 
tolerate PE [30]. The results of studies regarding stenting for DVT were inconsis-
tent, although some showed reduced severity in post-thrombotic syndrome and 
improved quality of life in some aspects [41–43]. This approach is therefore largely 
based on clinicians’ experience.
Stenting is considered if there is residual thrombi or residual venous outflow 
obstruction. It may also be considered when there is non-thrombotic cause of steno-
sis, such as in May-Thurner syndrome. Therefore, careful assessment of the lesion is 
important. It is helpful to combine other image modality such as computed tomog-
raphy or intravascular ultrasound. Besides anatomical nature, clinicians should put 
patients’ life expectancy, bleeding risk, and likelihood of symptom improvement 
into consideration. When a stent is placed, there is always risk of in-stent restenosis 
or occlusion. Risk factors include poor inflow, external compression, inappropriate 
stent design, stent misplacement or migration, stent fracture, and bleeding. Patients 
should be notified about the possibility of reintervention [44].
4.5 Summary of catheter-based therapy
The purpose of CBT is to relieve obstruction quicker, compared with tradi-
tional medical therapy. However, there is no strong evidence that CBT is better 
than traditional systemic thrombolysis since randomized trial assessing hard 
outcomes, such as mortality, is lacking. Also, among CBT, there is no trial compar-
ing catheter-directed thrombolysis and mechanical thrombectomy or comparing 
different devices. It is also important to remember that published studies for CBT 
with devices are of small patient numbers. There are many trials still going on. 
Hopefully, these trials will provide evidences for more specific guidance.
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For any intervention, there are always complications. Possible complications of 
CBT include access site bleeding, vascular injury, major bleeding (including intra-
cranial hemorrhage), distal emboli (especially of concern with PE when performing 
intervention for DVT), cardiac tamponade (intervention for PE), hemodynamic 
deterioration, and deterioration in renal function. Some studies did not demon-
strate the presumed benefit of less major bleedings (including intracranial hemor-
rhage) in percutaneous methods, compared with systemic thrombolysis [28, 29]. 
The balance between risk and benefit of these interventions should be personalized.
Generally speaking, CBT may be considered in patients with iliofemoral DVT 
who have severe symptoms and a low risk of bleeding [45]. For PE, CBT is an 
alternative to systemic thrombolysis and surgical embolectomy, considered when 
these approaches are contraindicated or fail [46]. For now, the choice of CBT largely 
remains on physicians’ experience and local availability.
5. Surgical embolectomy
Surgical intervention is an old skill compared with percutaneous intervention. 
Surgical embolectomy of PE requires cardiopulmonary bypass. After thoracotomy, 
emboli are removed manually with forceps. Balloon catheter and suction may be 
used for residual emboli. Although surgical embolectomy is a class I indication for 
massive pulmonary embolism, it is usually reserved as a salvage therapy when other 
therapies fail or are contraindicated, due to its invasive nature. If there is thrombus 
in right heart or thrombus across patent foramen ovale, surgical embolectomy 
would be considered the first-line therapy [27].
On the other hand, surgical thrombectomy for DVT is usually done with a 
special balloon catheter to pull out thrombi in the direction of venous flow, called 
Fogarty maneuvers [47]. Unlike for PE, surgical thrombectomy for DVT is not 
recommended by clinical guidelines. Although there are studies showing good 
patency rates after surgery, it is usually considered only in certain conditions when 
rapid reduction of venous obstruction is needed, such as in patients with phlegma-
sia cerulea dolens [48].
6. Conclusions
Although rapid evolution of modalities and relatively high successful rate in 
experienced center, routine use of endovascular or surgical thrombectomy and 
thrombolysis in patient with VTE is not recommended. To date, large-scale clinical 
trial assessing the efficacy and safety of invasive thrombolysis or thrombectomy 
is still lack. The application of endovascular or surgical strategies should be con-
sidered in selective VTE patients with unstable hemodynamic status or critical 
VTE-associated complications or having contraindications or high risk of bleeding 
while receiving systemic thrombolysis. In addition, future studies focusing on 
cost-effectiveness are needed to integrate these invasive procedures with medical 
strategies in the protocol of VTE treatment.
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